NCT00866983No Longer Available不适用
A Local, Multi-Centre, Extension, Open Label Access Study, To Provide Sildenafil Therapy For Patients Who Completed A1481244 Study And Are Judged By The Investigator To Derive Clinical Benefit From Continued Treatment With Sildenafil , Prior To Reimbursement And Availability For Patients In Brazil.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.1 个研究点 分布在 1 个国家开始时间: 2009年3月23日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 发起方
- 试验地点
- 1
研究概览
简要总结
The purpose of this study is to provide sildenafil therapy to patients who completed the A1481244 study for the treatment of PAH, and reside in Brazilian States where Revatio™ is not supplied by Health Secretary, and are judged by the Investigator to derive clinical benefit from continued treatment with Sildenafil. It will be supplied until patient gets access to Sildenafil through Brazilian State Health Secretary from where patient resides.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject who completed the A1481244 study and are judged by the Investigator to derive clinical benefit from continuous treatment with Sildenafil 20 mg therapy.
- •Subject who resides in a Brazilian State where Sildenafil is not supplied by State Health Secretary.
排除标准
- •Pregnant or lactating women.
- •Current participation in other studies and during study participation.
研究者
研究点 (1)
Loading locations...
相似试验
No Longer Available
不适用
An Open Label Access Study For Subjects Who Completed A1481156Pulmonary Arterial HypertensionNCT01582438Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
No Longer Available
不适用
Sildenafil Therapy For Subjects Who Derive Clinical Benefit From Continued Treatment With SildenafilPulmonary Arterial HypertensionNCT01897740Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
已完成
不适用
To Provide Sildenafil Therapy To Eligible Adult Patients With Pulmonary Arterial Hypertension For 112 WeeksPulmonary HypertensionNCT00946114Pfizer's Upjohn has merged with Mylan to form Viatris Inc.32
已完成
3 期
Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)Crohn's DiseaseNCT00338650Abbott1,000
终止
3 期
Investigational Drug in Patients With Hypercholesterolemia or in Patients With Sitosterolemia (0653-026)(COMPLETED)Hypercholesterolemia, FamilialLipid Metabolism, Inborn ErrorsNCT00092833Organon and Co49